

20030205236

FORM 100-100

FILE COPY

(2)

AD-A214 335

REPORT DOCUMENTATION PAGE

2b. DECLASSIFICATION/DOWNGRADING SCHEDULE		1b. RESTRICTIVE MARKINGS	
4. PERFORMING ORGANIZATION REPORT NUMBER(S) SR89-36		3. DISTRIBUTION/AVAILABILITY OF REPORT Approved for public release; distribution unlimited.	
5. MONITORING ORGANIZATION REPORT NUMBER(S)		7a. NAME OF MONITORING ORGANIZATION	
6a. NAME OF PERFORMING ORGANIZATION Armed Forces Radiobiology Research Institute		6b. OFFICE SYMBOL (if applicable) AFRRI	
6c. ADDRESS (City, State, and ZIP Code) Bethesda, MD 20814-5145		7b. ADDRESS (City, State, and ZIP Code)	
8a. NAME OF FUNDING/SPONSORING ORGANIZATION Defense Nuclear Agency		8b. OFFICE SYMBOL (if applicable) DNA	
9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER		10. SOURCE OF FUNDING NUMBERS	
8c. ADDRESS (City, State, and ZIP Code) Washington, DC 20305		PROGRAM ELEMENT NO. NWD QAXM	PROJECT NO.
		TASK NO.	WORK UNIT ACCESSION NO.
11. TITLE (Include Security Classification) (see reprint)			
12. PERSONAL AUTHOR(S) Raff et al.			
13a. TYPE OF REPORT Reprint	13b. TIME COVERED FROM TO	14. DATE OF REPORT (Year, Month, Day) 1988	15. PAGE COUNT 6
16. SUPPLEMENTARY NOTATION			
17. COSATI CODES		18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number)	
FIELD	GROUP	SUB-GROUP	
19. ABSTRACT (Continue on reverse if necessary and identify by block number)			
20. DISTRIBUTION/AVAILABILITY OF ABSTRACT <input type="checkbox"/> UNCLASSIFIED/UNLIMITED <input type="checkbox"/> SAME AS RPT. <input type="checkbox"/> DTIC USERS		21. ABSTRACT SECURITY CLASSIFICATION UNCLASSIFIED	
22a. NAME OF RESPONSIBLE INDIVIDUAL Gloria Ruggiero		22b. TELEPHONE (Include Area Code) (202) 295-2017	22c. OFFICE SYMBOL ISDP

SDTIC ELECTE D
NOV 09 1989
E

DD FORM 1473, 84 MAR

83 APR edition may be used until exhausted. All other editions are obsolete.

SECURITY CLASSIFICATION OF THIS PAGE
UNCLASSIFIED

89 11 08 013

L-LEUCYL-L-LEUCINE METHYL ESTER TREATMENT OF CANINE MARROW AND PERIPHERAL BLOOD CELLS

INHIBITION OF PROLIFERATIVE RESPONSES WITH MAINTENANCE OF THE CAPACITY FOR AUTOLOGOUS MARROW ENGRAFTMENT¹

ROBERT F. RAFF,² EILEEN SEVERNS, RAINER STORB, PAUL MARTIN, THEODORE GRAHAM,
BRENDA SANDMAIER, FRIEDRICH SCHUENING, GEORGE SALE, AND FREDERICK R. APPELBAUM

Fred Hutchinson Cancer Research Center, Seattle, Washington 98104

Cytotoxic T Lymphocyte
Natural Killer

Incubation of canine marrow and peripheral blood mononuclear cells with L-leucyl-L-leucine methyl ester resulted in the inhibition of mitogen- and alloantigen-induced blastogenesis, the elimination of allosensitized CTL and NK activity, and prevented the development of CTL from pCTL. The effects of these incubations were similar to those described in mice and humans. Additionally, in vitro CFU-GM growth from treated canine marrow was reduced, but could be regained when the Leu-Leu-OMe-treated marrow was cocultured with either untreated autologous peripheral blood mononuclear cells or monocyte-enriched PBMC but not with untreated monocyte-depleted PBMC. Six of seven dogs conditioned with 920 cGy total-body irradiation engrafted successfully after receiving autologous marrow that was incubated with Leu-Leu-OMe prior to infusion. These cumulative results indicate that incubation with Leu-Leu-OMe is a feasible method to deplete canine marrows of alloreactive and cytotoxic T cells prior to transplantation. *Start here* **Keywords:** Colony Forming Unit, Granulocyte, Macrophage.

The success of allogeneic marrow transplantation as treatment for malignant and nonmalignant hematopoietic diseases has been restricted by the serious complications of graft-versus-host disease (GVHD). Experiments in a variety of mammalian marrow transplant models have shown that removal of mature T cells from donor marrow permits engraftment without the development of GVHD. Based on these and similar observations, studies have been carried out to evaluate the effects of T cell depletion prior to allogeneic marrow transplantation in humans. Most studies have employed marrow treatments with anti-T cell monoclonal antibodies plus complement or with soybean agglutinin followed by E rosette formation and density gradient centrifugation (7-9). In general, removal of T cells has been associated with a marked decrease in both the incidence and severity of GVHD. However, the use of T cell-depleted marrow has also been associated with an increased incidence of marrow graft rejection (10).

¹ This work was supported by Grants CA31787 and CA18105 from the National Cancer Institute, National Institutes of Health, DHHS, and by contract DNA 001-86-C-0192 of the Defense Nuclear Agency, Armed Forces Radiobiology Research Institute. Views presented are those of the authors; no endorsement by the Defense Nuclear Agency has been given or should be inferred. Research was conducted according to the principles enunciated in the "Guide for the Care and Use of Laboratory Animals" prepared by the Institute of Laboratory Animal Resources, National Research Council.

² Address reprint requests to R. F. Raff, Fred Hutchinson Cancer Research Center, 1124 Columbia Street, Seattle, WA 98104.

Recently, Thiele and Lipsky have described a dipeptide methyl ester, L-leucyl-L-leucine-methyl ester (Leu-Leu-OMe)* that can eliminate natural killer cells (NK), monocytes (Mφ), and precursors of alloantigen-specific cytotoxic T cells (pCTL) from mouse spleen cell suspensions and from both mouse and human peripheral blood. This treatment leaves intact B cells, helper T cells, and murine erythroid and hematopoietic stem cells (11-14). In a murine histoincompatible marrow transplant model (C57BL/6J→(C57BL/6×DBA/2)F₁), treatment of donor marrow and spleen cells with Leu-Leu-OMe resulted in successful donor marrow engraftment and the development of stable long-term hematopoietic chimerism without GVHD (14-16). The use of Leu-Leu-OMe to treat marrow may have advantages over currently used methods. The use of Leu-Leu-OMe is very simple, requiring but a single 15-min incubation. In addition, it appears that marrow incubation with Leu-Leu-OMe results in the elimination of the cells responsible for acute GVHD while at the same time preserving hematopoietic stem cells needed for engraftment and the cells required for immune reconstitution (15, 16).

We and others have used dogs as a large, outbred animal model for us in experimental marrow transplantation (17, 18). The present studies were undertaken to determine whether the incubation of canine marrow and peripheral blood cells with Leu-Leu-OMe would yield alterations of in vitro cellular immune function comparable to those described in human and murine cells and to investigate the effects of marrow incubation with Leu-Leu-OMe on early hematopoietic progenitors and stem cells assayed for both in vitro and in vivo function.

MATERIALS AND METHODS

Dogs. Beagles, hounds, and mixed breed hounds, obtained from commercial vendors in Washington and Virginia or raised at the Fred Hutchinson Cancer Research Center (FHCRC), were dewormed and vaccinated against distemper, hepatitis, leptospirosis, and parvovirus before use in this study. All dogs were at least six months of age and were maintained at the FHCRC canine kennel facilities per guidelines stipulated by the National Academy of Sciences—National Research Council. The research protocol was approved by the Internal Animal Care and Use Committee at the Fred Hutchinson Cancer Research Center.

Medium. Waymouth's MB752/1 medium (FHCRC media preparation facility), supplemented with 0.1 mM nonessential amino acids and 100 U/ml penicillin and 100 μg/ml streptomycin (all from GIBCO),

* Abbreviations: Leu-Leu-OMe, L-leucyl-L-leucine-methyl ester; Mφ, monocytes; B-MLC, bulk MLC; NWN, nylon-wool nonadherent; CFU-C, colony forming unit in culture; PEDS, postendotoxin dog serum; CTAC, canine thyroid adenocarcinoma cell line.

was used for the dilution of heparinized whole blood and marrow for the cell separation procedures. Waymouth's medium supplemented as above with the addition of 10% to 20% heat-inactivated (56°C) normal pooled dog serum (M-NPS/10-20%) was used for the mixed leukocyte culture microassays, bulk MLC (B-MLC), cell-mediated lympholysis, and NK assays.

Cell preparation. Peripheral blood mononuclear cells were obtained by the centrifugation of heparinized venous whole blood (diluted 1:2 with medium) over Ficoll-Hypaque density gradients (Sp. density 1.074) as previously described (19). Bone marrow cells (BMC) for in vitro assays were obtained by syringe aspiration from the humeral head of an anesthetized dog. The marrow was diluted 1:2 with medium and overlaid onto Ficoll-Hypaque density gradients for centrifugation (1000 × g), following which the interface cells were washed once with hemolytic buffer and twice with medium. The PBMC and marrow cells were resuspended into medium for cell counts and viability assessment using the trypan-blue exclusion technique.

Monocyte-enriched cells were obtained by treating PBMC with the anticanine murine monoclonal antibody Dly 6 (20) as follows: 300 × 10⁶ PBMC were incubated for 30 min at room temperature in 30 ml of 1:100 diluted Dly 6 (ascites containing antibody), and then an equal volume of 1:2 diluted rabbit serum complement (Pel Freeze, Rogers, AR) was added for an additional 60 min. The cells were washed once with medium, resuspended in 30 ml of 1:3 diluted rabbit serum complement, and incubated again for 60 min. After washing twice in medium, these cell suspensions contained 61 ± 8% (SEM) viable monocytes, 16 ± 3% lymphocytes, and 23 ± 9% granulocytes, primarily eosinophils.

Monocyte-depleted PBMC were obtained by first passing PBMC over nylon-wool columns as previously described (21), and then transferring 30 × 10⁶ nylon-wool-nonadherent (NWN) cells in 10 ml of medium, containing 5% fetal calf serum, into plastic petri dishes (Falcon No. 3003, Lincoln Park, NJ) for 2 hr incubation at 37°C, 7% CO₂. This depletion technique yielded approximately 95 ± 1% lymphoid cells with greater than 90% viability and less than 3% monocytes as determined by morphologic assessment of Wright-stained cytospin preparations.

Preparation of Leu-Leu-OMe. The Leu-Leu-OMe was synthesized from L-leucyl-L-leucine (Sigma Chemical Co, St Louis, MO) as previously described (11). Qualitative assessment of Leu-Leu-OMe purity was obtained by thin-layer chromatography (TLC) (22). Briefly, 5 λ of 5 × 10⁻³ M solutions of L-leucine methyl ester (Leu-OMe) (dissolved in absolute methanol), L-leucine (Leu), L-leucyl-L-leucine (Leu-Leu) (both dissolved with heat and stirring in absolute methanol containing 0.5 N HCl), and the synthesized Leu-Leu-OMe were applied to pre-coated TLC plates (250 μ M, 10 × 20-cm, HPTLC Kieselgel 60 (Merck), Darmstadt, West Germany), and quickly dried under a stream of warm air. The plates were developed for 2.5-hr in an enclosed, equilibrated system containing the following mixture of reagent grade solvents: chloroform, absolute methanol and acetic acid at volume ratios of 19:0.6:12.5, respectively. The migrations of the four compounds were visualized by applying an aerosol spray of 0.2% ninhydrin in ethanol and then placing the plates in a 60°C oven for 30 min. R_f values (the ratio of the distance the compound travels to the distance the solvent front travels) were calculated, in order to assess the resultant migrations, according to the following formula (22):

$$R_f = \frac{\text{distance traveled by compound}}{\text{distance traveled by solvent front}}$$

Leu-Leu-OMe was stored at -20°C in absolute methanol and, based on repeated TLC analysis, was stable for at least three months.

Incubation of PBMC or marrow cells with Leu-Leu-OMe. Equal volumes of PBMC or marrow cell suspensions and Leu-Leu-OMe at the indicated final concentrations were incubated for 15 min at room temperature. Cells for in vitro studies were washed twice and resuspended in medium. Marrow cells used for autologous infusion were incubated at cell concentrations of 20 × 10⁶/ml in Leu-Leu-OMe solu-

tions that contained 0.1 U/ml DNAase (Worthington Enzymes and Biochemicals, Freehold NJ). After incubation, these cells were washed, counted, and reinfused within 1-3 hr.

Mixed leukocyte culture and mitogen assays. MLCs were established, labeled with [³H]thymidine, harvested, and prepared for liquid scintillation counting as previously described (23) with minor modifications. The 10⁶ Leu-Leu-OMe-treated or untreated responder and 10⁶ irradiated (2300 rads) untreated, stimulator PBMC were cocultured in a final volume of 200 μ l M-NPS/20% per well. Mitogen stimulation was assessed by adding either 375 μ g/ml PHA (DIFCO, Detroit MI), 200 μ g/ml Con A, (Calbiochem, San Diego CA), or 200 μ g/ml PWM (GIBCO, Grand Island, NY) to 10⁶ treated or untreated responder cells in a final volume of 200 μ l of M-NPS/20%. All cultures were established in triplicate in microtiter plates (Costar No. 3799, Cambridge MA) for 7 days at 37°C, 7% CO₂, in a humidified incubator.

Bulk MLC (B-MLC) and cell-mediated lympholysis assays. Bulk MLCs were established using either untreated or Leu-Leu-OMe-treated PBMC or marrow cells as responders, and untreated, irradiated PBMC as stimulators, to generate CTL for CML assays, as previously described (19), with modifications. CTL were derived from these cultures to form two CML assay groups: (1) responder PBMC or marrow cells treated with Leu-Leu-OMe or MeOH on day 0 prior to mixing with irradiated stimulator PBMC in B-MLC (day 0); and (2) Leu-Leu-OMe or MeOH treatment of 7-day B-MLC generated CTL (day 7). CTLs were mixed at a 50:1 effector:target ratio, with ⁵¹Cr-labeled ⁵¹Na CrO₄ (300-500 μ Ci/ml, NEN, Wilmington DE) Con A-stimulated PBMC targets. Cultures of PBMC to be used for targets in the CML assays were established on the same day of B-MLC, and stimulated with Con A on day 4 of culture. The 4-hr ⁵¹Cr release assay was performed as previously described (19). The mean spontaneous/maximum ⁵¹Cr release ratio was 16 ± 1% (\pm SEM), while maximum release/total ⁵¹Cr incorporation was 90 ± 2% for targets used in this series of CML assays.

Proliferation of treated or untreated responder PBMC or marrow cells in 7-day B-MLC was measured by distributing 200- μ l aliquots from each B-MLC flask into triplicate microculture wells and labeling for 7 hr with [³H]thymidine. Cell harvest and liquid scintillation counting were performed as described for MLC (23).

Natural killer cell (NK) assays. Leu-Leu-OMe or MeOH treated or untreated PBMC and marrow cells were assayed for NK activity against a ⁵¹Cr-labeled canine thyroid adenocarcinoma cell line (CTAC) in a 18-hr assay with the percentage of ⁵¹Cr release calculated as previously described (24).

In vitro marrow cultures for CFU-GM growth. Leu-Leu-OMe and MeOH treated and untreated marrow cells were tested for in vitro hematopoietic progenitor growth using an agar-based colony formation assay that utilizes postendotoxin dog serum (PEDS) as the source of colony-stimulating factor (25). Growth of granulocyte/macrophage colonies (CFU-GM) was assayed in cultures containing 10⁶ or 3 × 10⁶ treated or untreated marrow cells only, and in cultures in which marrow cells were cocultured with either 10⁶ autologous PBMC, Me-enriched or Me-depleted PBMC, or Leu-Leu-OMe treated PBMC (incubated with 1000 μ M Leu-Leu-OMe). Cultures were incubated in triplicate for 10 days in a 37°C, 7% CO₂ humidified incubator and GFU-GM colonies were enumerated as previously described (25).

Autologous marrow transplantation. Marrow for autologous transplantation was obtained by a vacuum pump aspiration procedure (26), processed over a Ficoll-Hypaque density gradient and incubated with Leu-Leu-OMe. All recipients were conditioned with 920 cGy total-body irradiation delivered as a single exposure from two opposing ⁶⁰Co sources at 7.0 cGy/min (26). The recipients were infused with treated autologous marrow within 3 hr of TBI. Supportive care pre- and posttransplantation with antibiotics, i.v. fluids, and whole-blood transfusions, was given as previously described (27). In addition, recipients were given oral antibiotics (Neomycin sulfate and polymyxin B sulfate) daily for five days before TBI and posttransplant until the granulocyte count reached 500/mm³.

RESULTS

Thin-layer chromatographic analysis of synthesized Leu-Leu-OMe. Three batches of Leu-Leu-OMe were synthesized for use in the *in vitro* studies and autologous transplant experiments described. Consistent R_f values were obtained for each batch of Leu-Leu-OMe and for the three control compounds tested. Within the Leu-Leu-OMe, there was a secondary spot that migrated with a R_f value equal to that observed for the L-Leucyl-L-leucine. The consistency of the R_f values indicated that constant yield and purity was achieved with minimal batch-to-batch variations.

Viability of PBMC and marrow cells after incubation with Leu-Leu-OMe. The viability of treated PBMC and marrow cells was assessed within 1 hr after incubation with Leu-Leu-OMe. There was no significant difference in viabilities observed in cells treated with either Leu-Leu-OMe (up to 1000 μ M), 0.5% MeOH in PBS, or PBS only. No time-course studies were done to assess the viability of PBMC and marrow cells more than 1 hr after incubation with Leu-Leu-OMe.

Elimination of alloantigen responsiveness and mitogen-induced lymphocyte blastogenesis by incubation of PBMC with Leu-Leu-OMe. PBMC were treated at either 2×10^6 or 20×10^6 /ml with Leu-Leu-OMe and tested in micro-MLC, and blastogenesis assays (Fig. 1). In all assays there was a Leu-Leu-OMe dose-dependent reduction in the proliferative response such that virtually no blastogenesis was observed after incubation with 1000 μ M Leu-Leu-OMe.

Treatment of 20×10^6 responder PBMC or marrow cells before bulk MLC resulted in similar Leu-Leu-OMe dose-dependent reductions in proliferative response (data not shown). The marrow cells gave a lower baseline level of [3 H]thymidine incorporation and were more sensitive than the PBMC to treatment with Leu-Leu-OMe (data not shown). Treatment of PBMC marrow cells with 0.5% MeOH in PBS had no effect on the alloplicative response in B-MLC (data not shown).

Elimination of the generation of antigen-specific cytotoxic T lymphocytes by incubation of PBMC and marrow cells with Leu-Leu-OMe. The effect of Leu-Leu-OMe on the generation of antigen-specific cytotoxic T cells was measured by incubating responder PBMC and marrow cells with Leu-Leu-OMe (day 0 treatment), and then testing these cells in a standard CML assay after 7 days of culture in B-MLC. Treatment with 1000 μ M Leu-Leu-OMe eliminated the generation of cytolytic activity against 51 Cr-labeled alloantigen-specific Con A-stimulated PBMC (Fig. 2). These results indicated that the generation of CTL from precursors is sensitive to incubation with Leu-Leu-OMe. The effect of Leu-Leu-OMe incubation on CTL already generated in 7-day bulk MLC (day 7 treatment) was also evaluated. This treatment eliminated antigen-specific cytolytic activity (Fig. 2). Treatment with 0.5% MeOH, either on day 0 or day 7, did not interfere with either the development of CTL or the specific cytotoxicity of targets assayed on day 7 (data not shown).

Elimination of NK activity after incubation of PBMC and marrow cells with Leu-Leu-OMe. Marked diminution of NK activity, in a dose-dependent manner, was seen after incubation of PBMC or marrow cells with Leu-Leu-OMe, and NK activity was essentially eliminated after treatment with 1000 μ M Leu-Leu-OMe (Fig. 3).

In vitro CFU-GM colony growth reduction by Leu-Leu-OMe




FIGURE 1. Effect of Leu-Leu-OMe on alloantigen- and mitogen-induced lymphocyte blastogenesis. Data for [3 H]thymidine incorporation are mean $\text{cpm} \pm \text{SEM}$ from multiple assays in which PBMC were treated at concentration of 2×10^6 or 20×10^6 cells/ml.




FIGURE 2. CML assays illustrating the effect of Leu-Leu-OMe treatment on p-CTL (day 0) or on 7-day B-MLC generated CTL (day 7), derived either from PBMC or BMC. The ordinate indicates mean percentage of ^{51}Cr release $\pm \text{SEM}$ using specific alloantigen-sensitizing ^{51}Cr -labeled Con A-stimulated PBMC as targets.




FIGURE 3. Leu-Leu-OMe treatment of PBMC and BMC eliminates NK cytotoxic activity. The ordinate indicates mean percentage of ^{51}Cr release $\pm \text{SEM}$ from CTAC at three different effector:target (E:T) ratios. For this series of assays, the mean spontaneous/maximum ^{51}Cr release ratio was $23 \pm 1\%$ ($\pm \text{SEM}$) and the maximum release/total ^{51}Cr incorporation ratio was $65 \pm 7\%$.

treatment of marrow cells. There was a marked reduction in CFU-GM colony growth obtained from marrow cells incubated with varying concentrations of Leu-Leu-OMe (Table 1). Minimal CFU-GM growth was observed with 10^6 Leu-Leu-OMe treated marrow cells per plate were cultured. There was some recovery of CFU-GM growth when the cell number was increased to 3×10^6 treated marrow cells per plate, but only to a level that was approximately 25% of that observed with 3×10^6 untreated marrow cells. Addition of either untreated, autologous PBMC or M ϕ -enriched autologous PBMC increased CFU-GM growth, but not to the levels observed with untreated marrow cells in similar cocultures. The addition of M ϕ -depleted or Leu-Leu-OMe treated autologous PBMC to treated marrow cells did not augment growth.

The effect of incubating marrow cells with Leu-Leu-OMe on autologous marrow engraftment. Six of the seven dogs given Leu-Leu-OMe treated autologous marrow engrafted and did so with kinetics similar to those seen in recipients of untreated autologous marrow (Table 2 and Fig. 4). Platelet counts returned to normal levels between 20 to 30 days posttransplant. Dog C521 did not survive past day 20 posttransplant. After Leu-Leu-OMe incubation, the marrow cells from this dog were clumped and had only 20% viability, resulting in the infusion of a very low marrow cell dose. The marrow from C580 was incubated with the same concentration of Leu-Leu-OMe as

C521, but the treated marrow cells of C580 did not clump and this dog survived with rapid engraftment. Dog BB8701 had to be euthanized on day 19 posttransplant due to an accidental, severe, foot injury that failed to respond to treatment, but did show evidence of engraftment as indicated by a rise in WBC and the marrow cellularity at autopsy.

DISCUSSION

Thiele and Lipsky have demonstrated that exposure of mouse spleen cells or human peripheral blood leukocytes to Leu-Leu-OMe depletes these populations of monocytes, NK cells, and cytotoxic lymphocytes at both the precursor and effector stages of differentiation, without apparently affecting other cell populations (11-13). They further showed that incubation of mixtures of murine marrow and spleen cells with Leu-Leu-OMe did not interfere with engraftment and could, in certain circumstances, prevent GVHD (14-16). In the studies presented here, we found that canine peripheral blood and marrow cells behave similarly following exposure to Leu-Leu-OMe with the elimination of functional monocytes, NK cells, and alloantigen sensitized CTL, and inhibited the development of CTL from pCTL. Further, we found that incubation of marrow cells with Leu-Leu-OMe (even at very high doses) did not inhibit autologous engraftment in recipients conditioned with 920 cGy TBI. These studies also demonstrated that the treatment of canine

TABLE 1. In vitro CFU-GM colony growth from marrow cells incubated with varying concentrations of Leu-Leu-OMe

Leu-Leu-OMe (μ M)	CFU-GM colonies obtained from CFU-C cultures*									
	10^6 BMC cocultures*					3×10^6 BMC cocultures*				
	No coculture	10^6 PBMC	10^6 M ϕ enriched	10^6 M ϕ depleted	10^6 Leu-Leu-OMe- treated PBMC	No coculture	10^6 PBMC	10^6 M ϕ enriched	10^6 M ϕ depleted	10^6 Leu-Leu-OMe- treated PBMC
Nil	66 \pm 13	84 \pm 9	96 \pm 15	76 \pm 23	78 \pm 13	207 \pm 15	255 \pm 18	348 \pm 9	288 \pm 7	252 \pm 17
250	0.4 \pm 0.2	64 \pm 32				55 \pm 31	178 \pm 65			
500	0	14 \pm 8				3 \pm 2	51 \pm 24			
1000	1.2 \pm 0.5	10 \pm 3	29 \pm 11	2 \pm 1	2 \pm 0.6	8 \pm 3	42 \pm 3	74 \pm 29	0.3 \pm 0.3	3 \pm 1
2000	2 \pm 1	5 \pm 2				2 \pm 0.8	13 \pm 5			
4000	0.7 \pm 0.6	11 \pm 5				0.9 \pm 0.5	16 \pm 9			

* Represented are mean values \pm SEM, obtained from multiple experiments in which triplicate CFU-GM cultures were established for each parameter tested.

^b All cocultures employed autologous cells. The limited yield of M ϕ prevented coculture with all concentrations of Leu-Leu-OMe tested. There was no CFU-GM growth when untreated PBMC (between 10^6 to 6×10^6 /ml) were cultured without marrow cells.

^c The concentration of marrow cells treated was constant at 20×10^6 /ml.

TABLE 2. Recipients conditioned with 920 cGy TBI and receiving Leu-Leu-OMe treated autologous marrow*

Dog ID	[Leu-Leu-OMe] ^a (μ M)	No. viable treated BMC infused (10^6 /kg) ^b	Survival (days post- BMT)	Cause of death	Marrow cellularity
C563	1000	1.4	152	Sodium pentothal ^c	Normocellularity (3 cell lines)
BB8701	1000	0.7	19	Sodium pentothal ^c	75% of Normocellularity (3 cell lines)
C622 ^d	1000	1.41	>124	Still living	Normocellularity (3 cell lines)
C521	2000	0.052	20	Pneumonia; sepsis.	Focal hematopoiesis
C580	2000	1.87	173	Sodium pentothal ^c	Normocellularity (3 cell lines)
B950	4000	1.3	114	Sodium pentothal ^c	Normocellularity (3 cell lines)
C662	4000	1.5	112	Sodium pentothal ^c	Normocellularity (3 cell lines)

^a Autologous marrow aspiration, BMC treatment, and infusion on same day as 920 cGy TBI to recipient (BMT: bone marrow transplant).

^b 2×10^6 BMC/ml treated with Leu-Leu-OMe.

^c Viability of bone marrow cells infused determined by trypan-blue stain exclusion technique.

^d Sodium pentothal injection for euthanasia at end of study.

^e The Leu-Leu-OMe-treated autologous marrow was frozen and stored at -80°C for one week prior to reinfusion. The procedure for marrow cryopreservation was as described (26).




FIGURE 4. Hematologic recovery in recipients conditioned with 920 cGy TBI and infused with Leu-Leu-OMe-treated autologous marrow. The ordinate indicates the absolute granulocyte counts obtained daily posttransplant until death or recovery to the normal range. The shaded area represents the normal range (mean \pm SD) of recovery observed in 16 dogs conditioned with 920 cGy TBI and given untreated autologous marrow (28).

marrow cells with Leu-Leu-OMe, in a concentration-dependent fashion, could reduce or eliminate *in vitro* CFU-GM growth. This reduction could be partially reversed with the addition of unfractionated autologous PBMC or M ϕ -enriched PBMC but not with M ϕ -depleted PBMC or autologous PBMC treated *in vitro* with Leu-Leu-OMe. Our assay employs postendotoxin-treated dog serum as a source of colony-stimulating factor. Reversal of the effects of Leu-Leu-OMe on CFU-GM growth by monocytes demonstrated the monocyte dependence of this CFU-GM assay system and suggests that PEDS does not act directly as a single factor on the granulocyte/macrophage progenitors.

Marrows were treated at two different cell concentrations in anticipation that this procedure might be useful for allogeneic marrow transplantation in large animals and possibly in man. Reduction or elimination of various cells involved either in response to alloantigen stimulation (MLC, pCTL, CTL) or NK function could be accomplished by treating PBMC or marrow cells at 20×10^6 /ml with $1000 \mu\text{M}$ Leu-Leu-OMe. The murine models using H2-disparate P \rightarrow F, marrow donor/recipient pairing showed that Leu-Leu-OMe treatment could prevent acute GVHD. The resultant chimeras developed normal cellular immune responses and showed donor and host-specific immunologic tolerance (16). The cell concentration treated in those studies was 2×10^6 /ml, and the highest concentration of Leu-Leu-OMe used was $250 \mu\text{M}$. Cell concentration directly influenced the concentration of Leu-Leu-OMe required to achieve a given effect. Thus, in the present study when the cell concentration was increased tenfold, the concentration of Leu-Leu-OMe had to be increased approximately fourfold to achieve the same inhibition of cellular immune functions. The potential problem of larger cell numbers and expanded marrow volumes needed for the transplantation of larger animals can be circumvented by increasing the concentration of Leu-Leu-OMe.

Data in the canine model suggest that Leu-Leu-OMe should be explored further as a possible substitute for other currently used methods of marrow T cell depletion. It needs to be determined whether treatment of marrow with Leu-Leu-OMe will

leave behind a population of cells that facilitate engraftment and recovery of immunity while removing cytotoxic T cells that may comprise the major population of cells involved in the development of acute GVHD.

Acknowledgments. We thank Ray Colby, Greg Davis, Susan DeRose, Cassandra Beckham, and the Fred Hutchinson Cancer Research Center hematology and pathology technical staffs for expert technical assistance during this study. We also thank Kendall of the FHRC Shared Word Processing facility for her excellent work in this manuscript preparation.

REFERENCES

1. Storb R, Thomas ED. Graft-versus-host disease in dogs and man: the Seattle experience. *Immunol Rev* 1985; 88: 215.
2. Storb R. Critical issues in bone marrow transplantation. *Transplant Proc* 1987; 19: 2774.
3. Korngold R, Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice: prevention by removing mature T cells from marrow. *J Exp Med* 1978; 48: 1687.
4. Kolb HJ, Rieder I, Rodt H, et al. Anti-lymphocytic antibodies and marrow transplantation: VI. Graft-versus-host tolerance in DLA-incompatible dogs after *in vitro* treatment of bone marrow with absorbed antithymocyte globulin. *Transplantation* 1979; 27: 242.
5. Wagemaker G, Vriesendorp HM, van Bekkum DW. Successful bone marrow transplantation across major histocompatibility barriers in rhesus monkeys. *Transplant Proc* 1981; 13: 875.
6. Vallera DA, Soderling CCB, Carlson GJ, Kersey JH. Bone marrow transplantation across major histocompatibility barriers in mice: effect of elimination of T cells from donor grafts by treatment with monoclonal Thy-1.2 plus complement or antibody alone. *Transplantation* 1981; 31: 218.
7. Martin PJ, Hansen JA, Buckner CD, et al. Effects of *in vitro* depletion of T cells in HLA-identical marrow grafts. *Blood* 1985; 66: 664.
8. Mitsuyasu RT, Champlin RE, Gale RP, et al. Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. *Ann Intern Med* 1986; 105: 20.
9. Reischer Y, Kapoor N, Kirkpatrick D, et al. Transplantation for severe combined immunodeficiency with HLA-A, B, D, DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. *Blood* 1983; 61: 341.
10. Storb R. The role of T cells in engraftment: experimental models, clinical trials. In: Gale RP, Champlin R, eds. *Progress in bone marrow transplantation*. New York: Liss, 1987: 23.
11. Thiele DL, Lipsky PE. Regulation of cellular function by products of lysosomal enzyme activity: elimination of human natural killer cells by a dipeptide methyl ester generated from L-leucine methyl ester by monocytes or polymorphonuclear leukocytes. *Proc Natl Acad Sci USA* 1985; 82: 2468.
12. Thiele DL, Lipsky PE. Modulation of human natural killer cell function by L-leucine methyl ester: monocyte-dependent depletion from human peripheral blood mononuclear cells. *J Immunol* 1985; 134: 786.
13. Thiele DL, Lipsky PE. The immunosuppressive activity of L-leucyl-L-leucine methyl ester: selective ablation of cytotoxic lymphocytes and monocytes. *J Immunol* 1986; 136: 1038.
14. Charley M, Thiele DL, Bennett M, Lipsky PE. Prevention of lethal murine graft-versus-host disease by treatment of donor cells with L-leucyl-L-leucine methyl ester. *J Clin Invest* 1986; 78: 1415.
15. Thiele DL, Charley MR, Calomeni JA, Lipsky PE. Lethal graft-versus-host disease across major histocompatibility barriers: requirement for leucyl-leucine methyl ester sensitive cytotoxic T cells. *J Immunol* 1987; 138: 51.
16. Thiele DL, Calomeni JA, Lipsky PE. Leucyl-leucine methyl ester

- treatment of donor cells permits establishment of immunocompetent parent → F₁ chimeras that are selectively tolerant to host alloantigens. *J Immunol* 1987; 139: 2137.
17. Vriesendorp HM, van Bekkum DW. Bone marrow transplantation in the canine. In: Shifine M, Wilson FD, eds. *The canine as a biomedical research model*. Oak Ridge, TN: DOE Technical Information Center, 1980: 153.
 18. Storb R, Deeg HJ. Contributions of the dog model in marrow transplantation. *Plasma Ther Transfus Technol* 1985; 6:303.
 19. Raff RF, Storb R, Ladiges WC, Deeg HJ. Recognition of target cell determinants associated with DLA-D-locus-encoded antigens by canine cytotoxic lymphocytes. *Transplantation* 1982; 40: 323.
 20. Wulff JC, Durkopp N, Aprile J, et al. Two monoclonal antibodies (DLY-1 and DLY-6) directed against canine lymphocytes. *Exp Hematol* 1982; 10: 609.
 21. Atkinson K, Deeg HJ, Storb R, et al. Canine lymphocyte subpopulations. *Exp Hematol* 1980; 8: 821.
 22. Pairis DL, Lampman GM, Kriz GS Jr. In: *Introduction to organic laboratory techniques*. Philadelphia: Saunders, 1976: 599.
 23. Raff RF, Deeg HJ, Farewell VT, DeRose S, Storb R. The canine major histocompatibility complex: population study of DLA-D alleles rising a panel of homozygous typing cells. *Tissue Antigens* 1983; 21: 360.
 24. Loughran TP Jr, Deeg HJ, Storb R. Morphologic and phenotypic analysis of canine natural killer cells: evidence for T cell lineage. *Cell Immunol* 1985; 95: 207.
 25. Raff RF, Deeg HJ, Loughran TP Jr, et al. Characterization of host cells involved in resistance to marrow grafts in dogs transplanted from unrelated DLA-non-identical donors. *Blood* 1986; 68: 861.
 26. Ladiges WC, Storb R, Graham T, Thomas ED. Experimental techniques used to study the immune system of dogs and other large animals. In: Gay WI, Heavner JE, eds. *Methods of animal experimentation; vol 7: research surgery and care of the research animal; part C*. Orlando, FL: Academic, (in press).
 27. Storb R, Rudolph RH, Kolb HJ, et al. Marrow grafts between DLA-A-matched canine littermates. *Transplantation* 1973; 15: 92.
 28. Deeg HJ, Meyers JD, Storb R, Graham TC, Weiden PL. Effect of trimethoprim-sulfamethoxazole on hematological recovery after total body irradiation and autologous marrow infusion in dogs. *Transplantation* 1979; 28: 243.

Received 28 March 1988.
Accepted 10 May 1988.

Accession For	
NTIS CRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By _____	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
A-1 20	

